
Novo Agrees to 2.6 Billion Dollar Weight Loss Pill Deal
Novo Nordisk will pay up to 2.6 billion dollars to Jiangsu Hengrui Pharmaceuticals for rights to an experimental weight loss pill. The agreement strengthens the drugmaker's pipeline against competitors in the growing GLP-1 market.
Xurve View
Insights:
Xurve View

NOVO NORDISK A/S-B agreed to pay up to $2.6 billion to JIANGSU HENGRUI PHARMACEUT-H on Tuesday morning for global rights to an experimental weight-loss pill. The transaction expands the Denmark-based drugmaker's pipeline through a second GLP-1 partnership in China. The move helps Novo counter market pressure from competitors like ELI LILLY & CO as key patents approach expiration.









